Drug Profile
Trastuzumab biosimilar - Alteogen/Cristalia/Qilu Pharmaceutical
Alternative Names: ALT 02; ALT L2; ALT LS2; Herceptin biosimilar; QL-1701Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alteogen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
- Preclinical Gastric cancer
Most Recent Events
- 13 Oct 2021 Phase-II clinical trials in Breast cancer (In volunteers) in Canada (IV) (Alteogen pipeline, October 2021)
- 13 Oct 2021 Preclinical development is still ongoing for Breast cancer and Gastric cancer in South Korea (SC) (Alteogen pipeline, October 2021)
- 28 May 2020 No recent reports of development identified for phase-I development in Breast-cancer in Canada (IV)